EFFICACY AND SAFETY OF SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO LBEC0101 (ETANERCEPT BIOSIMILAR) COMPARED WITH CONTINUING LBEC0101 IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：3
|
作者：
Song, Y. W. [1 ]
Matsuno, H. [2 ,3 ]
Park, M. -C. [4 ]
Tomomitsu, M. [5 ]
Shin, S. [6 ]
Lee, J. [6 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul, South Korea
[2] Tokyo Med Univ, Tokyo, Japan
[3] Matsuno Clin Rheumat Dis, Toyama, Japan
[4] Yonsei Univ, Div Rheumatol, Coll Med, Seoul, South Korea
[5] Mochida Pharmaceut Co Ltd, Tokyo, Japan
[6] LG CHEM, Seoul, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1316
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0456
引用
收藏
页码：1389 / 1390
页数：3
相关论文
共 50 条
  • [1] LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis
    Song, Yeong Wook
    Park, Yong-Beom
    Kim, Jinseok
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 1 - 8
  • [2] Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
    Park, Min-Chan
    Matsuno, Hiroaki
    Kim, Jinseok
    Park, Sung-Hwan
    Lee, Sang-Heon
    Park, Yong-Beom
    Lee, Yun Jong
    Lee, Sang-Il
    Park, Won
    Sheen, Dong Hyuk
    Choe, Jung-Yoon
    Choi, Chan-Bum
    Hong, Seung-Jae
    Suh, Chang-Hee
    Lee, Shin-Seok
    Cha, Hoon-Suk
    Yoo, Bin
    Hur, Jin-Wuk
    Kim, Geun-Tae
    Yoo, Wan-Hee
    Baek, Han Joo
    Shin, Kichul
    Shim, Seung Cheol
    Yang, Hyung-In
    Kim, Hyun Ah
    Park, Kyung-Su
    Choi, In Ah
    Lee, Jisoo
    Tomomitsu, Masato
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [3] Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
    Min-Chan Park
    Hiroaki Matsuno
    Jinseok Kim
    Sung-Hwan Park
    Sang-Heon Lee
    Yong-Beom Park
    Yun Jong Lee
    Sang-Il Lee
    Won Park
    Dong Hyuk Sheen
    Jung-Yoon Choe
    Chan-Bum Choi
    Seung-Jae Hong
    Chang-Hee Suh
    Shin-Seok Lee
    Hoon-Suk Cha
    Bin Yoo
    Jin-Wuk Hur
    Geun-Tae Kim
    Wan-Hee Yoo
    Han Joo Baek
    Kichul Shin
    Seung Cheol Shim
    Hyung-In Yang
    Hyun Ah Kim
    Kyung-Su Park
    In Ah Choi
    Jisoo Lee
    Masato Tomomitsu
    Seonghye Shin
    Jiyoon Lee
    Yeong Wook Song
    Arthritis Research & Therapy, 21
  • [4] LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects
    Heechan Lee
    Hyewon Chung
    SeungHwan Lee
    Howard Lee
    Sung Mo Yang
    Seo Hyun Yoon
    Joo-Youn Cho
    In-Jin Jang
    Kyung-Sang Yu
    BioDrugs, 2017, 31 : 349 - 355
  • [5] LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects
    Lee, Heechan
    Chung, Hyewon
    Lee, SeungHwan
    Lee, Howard
    Yang, Sung Mo
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Jang, In-Jin
    Yu, Kyung-Sang
    BIODRUGS, 2017, 31 (04) : 349 - 355
  • [6] Comparison of safety and effectiveness between etanercept biosimilar LBEC0101 and reference in patients with rheumatoid arthritis in real-world data using the KURAMA cohort
    Kawakami, Tomoya
    Masui, Sho
    Onishi, Akira
    Onizawa, Hideo
    Fujii, Takayuki
    Murakami, Kosaku
    Murata, Koichi
    Tanaka, Masao
    Shimada, Takashi
    Nakagawa, Shunsaku
    Matsuda, Shuichi
    Morinobu, Akio
    Terada, Tomohiro
    Yonezawa, Atsushi
    MODERN RHEUMATOLOGY, 2024, 34 (06) : 1135 - 1141
  • [7] LBEC0101, AN ETANERCEPT BIOSIMILAR, SHOWED COMPARABLE TOLERABILITY AND PHARMACOKINETIC PROFILES TO THOSE OF ETANERCEPT IN HEALTHY MALE VOLUNTEERS
    Chung, H.
    Ahn, L.
    Choi, Y.
    Shin, S.
    Jang, I.
    Yu, K.
    Lee, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S5 - S6
  • [8] LBEC0101, AN ETANERCEPT BIOSIMILAR, SHOWED COMPARABLE TOLERABILITY AND PHARMACOKINETIC PROFILES TO THOSE OF ETANERCEPT IN HEALTHY MALE VOLUNTEERS.
    Chung, H.
    Ahn, L.
    Choi, Y.
    Shin, S.
    Jang, I.
    Yu, K.
    Lee, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S39 - S39
  • [9] A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate
    Matsuno, Hiroaki
    Tomomitsu, Masato
    Hagino, Atsushi
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [10] Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate
    Matsuno, Hiroaki
    Tomomitsu, Masato
    Hagino, Atsushi
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 488 - 494
12345